Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day:
Pharmacoepidemiologic study with a US nationwide health insurance claim database suggests SGLT-2 inhibitors are associated with a lower risk of myeloma, possibly due to SGLT2-mediated tumor-suppressing activities.”
Title: SGLT-2 Inhibitors are Associated With a Lower Risk of Multiple Myeloma
Authors: Enze Liu, Anna Sun, Yuedi Yang, Jing Xu, Attaya Suvannasankha, Brian A. Walker, Pengyue Zhang
You can read the full article on European Journal of Haematology.
You can find other articles featuring Robert Orlowski on OncoDaily.
